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Tumor angiogenesisCoagulation abnormalities occur frequently in cancer patients. It is becoming evident that blood platelets have
an important function in this process. However, understanding of the underlying mechanisms is still very
modest. In this review, we discuss the role of platelets in tumor angiogenesis and growth and suggest their
potential signiﬁcance in malignancies. Platelets contain various pro-and antiangiogenic molecules, which
seem to be endocytosed and sequestered in different populations of α-granules. Furthermore, tumor
endothelial cells are phenotypically and functionally different from endothelial cells in healthy tissue,
stimulating local platelet adhesion and subsequent activation. As a consequence, platelets are able to secrete
their angiogenic and angiostatic content, most likely in a regulated manner. The overall effect of these
platelet–endothelium interactions appears to be proangiogenic, stimulating tumor angiogenesis. We favor the
view that local adhesion and activation of blood platelets and dysregulation of coagulation represent
underestimated pathways in the progression of cancer.31 20 4443844.
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Platelet functioning in hemostasis and coagulation has been
widely studied for a long time, resulting in our current understanding
of platelet behavior in physiological and pathological conditions. In
addition to their role in hemostasis, platelets have also been
implicated in malignant diseases. It is not uncommon for cancer
patients to develop coagulation abnormalities, in which platelet
functioning may be markedly disturbed as well. These abnormalities
were unexplained for a long time, but over the last few years
numerous data have been obtained suggesting the involvement of
platelets in tumor development and growth.
Angiogenesis, which is the process of new blood vessel growth
from pre-existing vessels, is imperative in malignant tumor growth. It
is regulated by a balance of proangiogenic and angiostatic factors,
which, upon the switch of tumor cells to an angiogenic phenotype,leads to tumor growth and progression [1]. Since angiogenesis
research got an enormous boost after the early 1990s, different
angiogenesis regulators have been discovered. Vascular endothelial
growth factor (VEGF) and basic ﬁbroblast growth factor (bFGF) were
identiﬁed as positive regulators of angiogenesis. Interferon-α,
angiostatin, endostatin and TNP-470 are examples of the ﬁrst
generation of angiogenesis inhibitors, while compounds such as
bevacizumab, sunitinib and erlotinib are examples of current clinically
used compounds [2]. During the past years several of these
angiogenesis inhibitors have found their way into mainstream
oncology treatment [3]. Very oftenly angiogenesis inhibitors are
used in combination with chemotherapy to extend progression free
survival in various malignant diseases such as colorectal, lung, and
breast cancer [4–6]. Effective use of angiogenesis inhibitors as
monotherapy for cancer has thus far been mainly limited to renal
cancer [7]. Fundamental research as well as these clinical applications
demonstrated that tumor endothelial cells are a particularly suitable
target for cancer therapy, as they play an essential role in
angiogenesis. The fact that they are easily accessible for intravenously
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susceptible to drug-induced resistance after prolonged treatment [8],
illustrates the attractiveness of angiogenesis inhibition as a treatment
modality against cancer.
Platelets have been associated with malignant diseases since the
late 19th century, as different abnormalities were observed in the
coagulation and hemostasis systems of cancer patients [9]. These
patients are at increased risk of different thromboembolic events such
as venous thromboembolism, including deep vein thrombosis and
pulmonary embolism [10]. Laboratory tests also indicate a variety of
irregular platelet related values in the blood of cancer patients, e.g.
raised platelet counts, increased platelet turnover and elevated
concentrations of ﬁbrinogen breakdown products [11–14]. A relation
between platelets and tumor angiogenesis is suggested by the fact
that platelets appear to be the main physiologic transporters of VEGF
[15]. This hypothesized link is supported by experimental data
showing that platelets release their VEGF content upon activation
[16,17] and that they are activated in tumor vasculature, enabling
them to secrete their content locally within the malignant tissue [18].
Actual involvement of platelets in angiogenesis is illustrated by their
modulating function in gastric ulcer healing, a process known to be
dependent on VEGF and angiogenesis [19,20], and also by the ﬁnding
that they stimulate capillary growth in matrigel, which is indicative of
their capability to stimulate endothelial cells to transform into vessel
like structures [21]. The functional relevance of platelets in tumor
angiogenesis in vivo has been demonstrated in a cornea assay in
which lack of platelets led to haemorrhage during angiogenesis, while
platelet depletedmice showed an inhibition of early angiogenesis and
intratumor haemorrhage [22]. In addition, thrombocytopenic tumor
bearing mice show reduced tumor cell proliferation and growth, and
increased tumor necrosis [23]. Several reports, showing that the
inhibition of platelet function in cancer patients not only reduces the
number of thromboembolic events, but also results in reduction of
tumor growth and risk of relapse [24–29], underline the notion of a
possible role of platelets in tumor angiogenesis.
The data mentioned above support the idea that platelets are
positively involved in tumor angiogenesis and growth. The question of
which mechanisms underlie platelet mediated angiogenesis remains.
This review will ﬁrst present a short overview of current knowledge
on platelet functioning in hemostasis and thrombosis, then summa-
rize data that support the hypothesized role of platelets in tumor
angiogenesis, and end with the potential meaning of the involvement
of platelets for cancer therapy.
2. Platelet functioning during hemostasis and thrombosis
Platelets play a central role in hemostasis, limiting blood loss after
injury, but also in thrombosis, inﬂammation, and restenosis. Under
physiological conditions, endothelial cells prevent platelets from
binding to the vessel wall; platelets ﬂow in the blood stream in close
proximity to the endothelium, but rarely adhere to it [30,31].
Endothelial cell damage or alteration may lead to exposure of the
subendothelial extracellular matrix (ECM), whereafter platelets can
come into contact with thrombogenic components of the ECM. The
ECM contains variousmacromolecules that are appropriate ligands for
platelet adhesion. These molecules include different types of collagen,
von Willebrand factor (vWF), laminin, vitronectin, proteoglycans,
thrombospondin, and ﬁbronectin [32].
The hemostatic response to endothelial damage or alteration
depends on the extent of the injury, the local ﬂuid dynamic conditions
and the speciﬁc ECM components that are exposed [32]. Of these
components, especially collagen and vWF are important for platelet
adhesion and also for platelet activation [33]. Under high shear
conditions, platelet adhesion to the vessel wall is strictly dependent
on vWF that is bound to collagen. Soluble vWF does not bind to
circulating platelets, but when it is immobilized on a collagen surfacehigh shear stress induces conformational changes, resulting in a fast,
reversible interaction with platelet glycoprotein (GP) Ib-V-IX [34].
This interaction reduces platelet ﬂow velocity and results in rolling of
the platelets over the collagen surface. In addition, vWF can also bind
to GPIIbIIIa (integrin αIIbβ3) on the platelet membrane. As a result,
vWF can function as a bridge between platelets and collagen [35].
Platelet rolling may enable direct interactions between platelets and
collagen, resulting in ﬁrm adhesion. Platelets adhere to collagen
through two receptors, GPVI and GPIa-IIa (integrin α2β1) [31,36].
Direct adhesion of platelets to collagen induces their activation,
increasing their cytosolic free calcium concentration [37]. This is
accompanied by shape change and by exposure of phosphatidyl-
serine (PS) on the outer platelet membrane, which turns the platelets
procoagulant [38].
Activated platelets that adhere to collagen can recruit other
platelets from the blood stream to form an aggregate. Activation of
these newly recruited platelets is caused by the release of autocrine
agents, partly from secretory granules. The α-granule, which is the
most abundant granule in platelets, contains amultifunctional array of
proteins such as vWF, ﬁbrinogen, thrombospondin and P-selectin.
Another type of secretory vesicles in platelets are the dense granules.
They serve as storage pools for serotonin, adenosine diphosphate
(ADP), adenosine triphosphate (ATP) and the divalent cations Ca2+
andMg2+ [39–42]. Two of themolecules that are especially important
during the formation of a platelet aggregate are ADP and thromboxane
A2 (TXA2). TXA2 is formed from arachidonic acid, which is released
from membrane phospholipids by phospholipase A2 upon platelet
activation. TXA2 diffuses through the cell membrane and activates
other platelets by binding to their thromboxane-prostanoid (TP)
receptors, TPα and TPβ [43]. ADP, secreted from the dense granules,
activates platelets via the receptors P2Y1 and P2Y12; P2Y1 activation
mediates shape change and initiates aggregation, while P2Y12 is
needed to complete and amplify the aggregation process [31,44,45].
Procoagulant platelets accelerate the formation of thrombin from
prothrombin. Thrombin is a crucial protein linking coagulation,
platelet activation and thrombus formation [46]. It is one of the
strongest platelet agonists known, and binds to the protease-activated
receptors PAR-1 and PAR-4. PAR-1 is responsible for the majority of
the thrombin response and responds to low concentrations of
thrombin, while PAR-4 only responds to higher concentrations of
thrombin [47]. Thrombin also catalyzes the formation of ﬁbrin from
ﬁbrinogen. Fibrinogen, which is found both in plasma and in α-
granules, is involved in the aggregation process as well. It has binding
sites for integrin αIIbβ3 on both ends, and acts as a bridging molecule
between aggregating platelets [48]. Fibrin stabilizes the aggregate and
consolidates the resulting thrombus or haemostatic plug.
3. Platelets are involved in the regulation of the angiogenic
balance in tumors
Beside molecules involved in hemostasis and thrombosis, platelet
secretory granules also contain various proteins that regulate
angiogenesis (Table 1). Platelets are for example reported to be the
main physiologic transporters of VEGF, which is one of the most
potent proangiogenic factors known [15]. They take up such
angiogenesis regulatory factors in a dose-dependent manner by
active endocytosis and sequester these proteins in their α-granules
[49]. Beside the selective uptake of endogenous angiogenesis
regulatory proteins, platelets also endocytose intravenously admin-
istered monoclonal antibodies, like bevacizumab. When this anti-
VEGF antibody is taken up in the α-granules, it neutralizes VEGF [50].
This results in reduced platelet angiogenic activity, whichmay explain
the clinical side effects of bevacizumab treatment [50].
The fact that platelets contain so many proteins that regulate
angiogenesis underlines their potential signiﬁcance in tumor devel-
opment and growth. Yet, in order for these substances to be released
Table 1
Platelet-derived angiogenesis stimulators and inhibitors.
Platelet-derived angiogenesis
stimulators
Platelet-derived angiogenesis
inhibitors
VEGF [16] TGF-β [130]
PDGF [131] Endostatin [19]
EGF [132] Angiostatin [133]
BFGF [134] PF4 [135]
IGF I [136] PF4 fragments [137]
IGF II [136] CXCL4L1 [138]
HGF [130] Thrombospondin [139]
PD-ECGF [140] PAI-1 [141]
Ang-1 [142] HGF domain NK1 [56]
MMPs [143–145] HGF domain NK2 [56]
S1P [146]
SDF-1 [147]
Fig. 1. Activation of speciﬁc platelet receptors stimulates the selective release of either
VEGF or endostatin from speciﬁc α-granules. PAR-1 stimulation results in the release of
VEGF while inhibiting endostatin secretion, whereas PAR-4 stimulation induces
endostatin release and inhibits secretion of VEGF. VEGF release in response to P2Y
stimulation is signiﬁcantly less when compared to PAR-1 stimulation.
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vasculature. This has been shown to be the case in different cancer
types. Verheul et al. have shown that platelets are activated in tumor
vasculature of soft tissue sarcomas by applying immunoconfocal
microscopy of tumor tissue and by measuring coagulation markers in
tumor aspirates [18]. Tissue factor (TF) concentration was approxi-
mately twice as high, and thrombin concentration showed a 63-fold
increase when compared to normal plasma values. Tumor tissue
showed dense vascularization with intense VEGF expression and the
presence of activated platelets. These platelets were associated with
ﬁbrinogen in aggregates as was shown by double staining for αIIbβ3
integrin and ﬁbrin(ogen). Other groups have demonstrated platelet
activation in different malignancies such as breast and prostate
cancer, where increased plasma levels of soluble P-selectin and
ﬁbrinogen were found when compared to controls [51,52].
Increased expression of TF by tumor endothelial cells may
contribute to the localized activation of platelets in the tumor vessels.
TF is an integral membrane protein that initiates the coagulation
cascade after binding to factor VII/VIIa, ultimately leading to the
formation of platelet activating thrombin [47,53]. A signiﬁcant relation
between TF expression and microvessel density, and between TF and
VEGF has been found in breast cancer [54,55]. Increased expression of
TF has also been observed in many other tumor types, including small
cell carcinoma, bronchoalveolar carcinoma, head and neck cancer,
malignant glioma, bladder cancer, and prostate cancer [56–58]. Solid
tumors have been shown to express TF on their endothelial cells as
well as on the tumor cells themselves [58,59]. Furthermore, stimula-
tion of human umbilical vein endothelial cells (HUVECs) with bFGF
leads to TF expression by these cells [54]. The same holds for VEGF;
there is increasing evidence suggesting that VEGF induces endothelial
cells in tumor vasculature to express TF [60–64]. Moreover, transfec-
tion of TF in different tumor cell lines results in an upregulation of
VEGF secretion from these cells suggesting a regulatory function of TF
in proangiogenic and antiangiogenic properties of tumor cells [62,65].
There is also evidence of high concentrations of thrombin within
tumors, most likely as a result of an increased TF expression in tumors
[66]. TF and thrombin are not the only platelet activating factors in
tumors; B16F1 and B16F10murinemelanoma cell lines, and 253J cells
have been shown to activate platelets by an ADP dependent
mechanism [67]. Therefore, one could hypothesize that tumors
promote platelet activation and aggregation in their vasculature by
the expression and/or release of platelet activating factors such as TF,
thrombin and ADP, resulting in the release of angiogenesis regulatory
factors fromplatelet granules, which in turn affects tumor growth [68].
Although platelets contain both angiogenic and angiostatic com-
pounds, their overall effect on angiogenesis seems to be stimulating
[41,69]. Several recent studies have provided evidence that suggest that
the secretion of the angiogenic and angiostatic proteins by platelets is a
regulated process. The group of Folkman showed that angiogenic and
angiostatic proteins are organized into separate populations of α-granules [40]. They and others alsoprovideddata that suggest that these
proteins can be secreted differentially by selective stimulation of the
thrombin receptors PAR-1 and PAR-4 [40] or by ADP dependent platelet
activation through the P2Y receptors [70]. Ma et al. were the ﬁrst to
demonstrate a link betweenPAR-1 and PAR-4 stimulation and release of
either VEGF or endostatin from platelet granules, leading to evidence of
a counter-regulatory modulation of angiogenic compound release by
stimulation of these thrombin receptors [20]. Selective PAR-1 stimula-
tion leads to VEGF release, while at the same time the secretion of
endostatin from platelets is inhibited. By contrast, PAR-4 activation
results in the secretionof endostatin,whileVEGF secretion is suppressed
[40]. Moreover, PAR-1 inhibition in rats decreases gastric ulcer healing,
which is known to be dependent on VEGF [20]. Together these ﬁndings
suggest a regulatory role for platelet PAR receptors in angiogenesis and,
hence, in tumor growth.
ADP-mediated platelet activation seems to have a regulatory effect
on VEGF and endostatin release as well [70]. After stimulation with
ADP via either or both P2Y receptors, platelets secrete signiﬁcant
amounts of VEGF, but almost no endostatin. As compared to thrombin
receptor activation, ADP activation appeared to be a weaker stimulus
for VEGF release. This is consistent with the role of ADP as a relatively
weak platelet agonist when compared to thrombin [70]. Overall, these
results suggest the involvement of platelets and their PAR en P2Y
receptors in regulation of the angiogenic balance in tumors by
selective secretion of pro- and antiangiogenic factors (Fig. 1).
Platelets are also able to inﬂuence angiogenesis by shedding of
microparticles. Microparticles are small vesicles originating from
plasma membranes and can be produced by various cells, e.g.
endothelial cells, leukocytes, erythrocytes, megakaryocytes and plate-
lets. Microparticles are different from exosomes, which are released
from endocytic multivesicular bodies [71]. The cellular origin of
microparticles can be established on the basis of their surface antigens;
plateletmicroparticles (~b0.5 μm)express CD41 and/or CD42b antigens
[72,73]. There is increasing evidence showing the potential of these
submicron fragments of platelets and their role in normal physiology
Table 2
Selected platelet adhesion molecules and their (sub)endothelial ligands, possibly
involved in tumor angiogenesis.
Platelet adhesion
molecules
Major (sub)endothelial ligands
Integrin α2β1 Collagen, laminin [88,101]
Integrin α5β1 Fibronectin [88,101]
Integrin α6β1 Laminin [88,101]
Integrin ανβ3 Fibronectin, vitronectin, vWF,
osteopontin, thrombospondin
[88,101,115,148]
Integrin αIIbβ3 Fibrin(ogen), ﬁbronectin, vWF,
vitronectin, thrombospondin
[101,115,148]
GPIb-IX-V
(incl. GP1bα)
vWF, P-selectin [101,106,148]
GPVI Collagen, laminin [36,101,149]
PSGL-1 P-selectin [106]
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(PMPs) in normal thrombosis and homeostasis is well deﬁned, as
platelets shed their particles upon activation at the site of injury.
However, their importance in most other diseases is unknown and
mostly based on in vitro studies. There are indications suggesting that
after attachment or fusion with target cells, PMPs deliver cytoplasmic
proteins and genetic material (RNA) to recipient cells, e.g. tumor cells.
This way they function as a transport delivery system of bioactive
molecules involved in homeostasis and thrombosis, immunity, inﬂam-
mation and tumor growth and angiogenesis [74,75]. This transfer of
bioactive material can affect the recipient cell function. Hematopoietic
stem-progenitor cells that are covered with PMPs are able to express
numerous plateletmembrane receptors such as CD41, CD62, CXCR4 and
PAR-1 [76].
Knowledge about the role of PMPs in malignant diseases is only
beginning to develop [74]. It is known that some cancer cell types are
able to trigger platelets at tumor sites, inducing activation and
aggregation, which results in increased local and systemic concentra-
tionsof PMPs. The circulatingPMPconcentrationhas been shown tobe a
prognostic marker for gastric cancer and metastatic disease, even more
thanplasma levels of interleukin-6 andVEGF [77]. In addition, high PMP
concentrations are strongly correlated with aggressive tumors and
appear to be linked with reduced overall survival [78]. PMPs are also
able to stimulate the secretion of matrix metalloproteinase-2 (MMP-2)
fromprostate cancer cells in vitro, a secretionwhichwas independent of
other platelet-derived angiogenic factors, like VEGF, PF-4 and bFGF [79].
The role of PMPs in angiogenesis is becomingmore evident as several in
vitro studies have shown that PMPs are able to induce angiogenesis, by
stimulating the proliferation, migration, survival and tube formation of
human umbilical vein endothelial cells (HUVECs) [80]. Additionally,
PMPs also promote sprouting of blood vessels in vitro and in vivo, an
effect mediated by intra-particle FGF and VEGF [81]. Altogether, these
data suggest a role of platelet-derivedmicroparticles in the involvement
of platelets in tumor angiogenesis.
4. Enhanced platelet adhesion in tumor blood vessels affects
tumor angiogenesis
A prerequisite for local platelet activation and secretion of
angiogenesis regulatory proteins is that they have to adhere to
endothelial cells or exposed ECM components inside the tumor.
Several studies have provided data suggesting an increase in platelet
tethering and adhesion in tumor vasculature or in a tumor-like
environment [18,82–88]. For instance, platelet adhesion to HUVECs
increased 2.5-fold after stimulation with VEGF [18], while a N3-fold
increase was observed in angiogenic vessels in a mouse skin chamber
with implanted matrigel, when compared with mature skin vessels
[22]. These data suggest that a pro-angiogenic environment changes
the antithrombogenic surface of endothelial cells into a prothrombo-
genic state, which may lead to platelet adhesion and activation in
tumor vasculature. Beside adhering to endothelial cells, platelets can
also interact with tumor cells, which initiates the process of tumor
cell-induced platelet aggregation (TCIPA); this process is implicated
in hematogenous tumormetastasis and growth [89,90]. The process of
TCIPA appears to involve a number of platelet adhesion molecules,
and results in platelet activation and aggregation around the tumor
cells, with release of their pro- and antiangiogenic content [91]. Taken
together, platelet receptors may provide attractive targets to reduce
tumor angiogenesis, growth and metastasis, for example by selective
blockade of such adhesion molecules on platelets or their endothelial
and/or subendothelial ligands (Table 2) [18].
One family of adhesion molecules involved in platelet–endothelial
interactions are the integrins. Integrins are heterodimeric transmem-
brane receptors and consist of non-covalently associated α and β
subunits. Endothelial cells express several integrins that bind to
components of the subendothelial ECM; several of these integrins areinvolved in the regulation of endothelial cell growth and migration
during angiogenesis [88]. Inhibition of these integrins by antibodies or
low molecular weight antagonists leads to prevention or inhibition of
vessel formation in different angiogenesismodels [88,92–100]. Platelets
express 5 integrins on their cell surface (Table 2) [101]. Both β3-
integrins andα5β1 engage ECM ligands that contain the canonical Arg–
Gly–Asp (RGD) motif. Binding of integrins to their ligands requires a
conformational change froma low-afﬁnity toa high-afﬁnity state,which
occurs during platelet activation. The coincidence of platelet adhesion
and activation in tumor vessels may lead to local secretion of
angiogenesis regulatory proteins and, hence, regulation of tumor
angiogenesis. In various studies, the antiangiogenic potential of several
inhibitors of integrins is tested [93,99,102–104]. One should realize,
however, that such treatmentmay not only affect interactions between
platelets and vesselwall components, but also thebindingof endothelial
cells to ECM proteins. Therefore, one should be aware that the role of
platelets and their integrins in tumor angiogenesis cannot be simply
deduced from data obtained in such studies.
vWF is one of the endothelial adhesion molecules potentially
involved in platelet–endothelial interactions; it can bind to platelet
integrins αvβ3 and αIIbβ3, and to GPIb-IX-V. vWF is upregulated on
activated endothelial cells [87]. Interaction between vWF and platelet
GPIb-IX-V results in platelet rolling over the endothelium andmay lead
to ﬁrm adhesion and activation of the platelets [32]. However, Kisucka
and colleagues did not ﬁnd any angiogenesis defect in mice deﬁcient in
vWFusing the cornea angiogenesis assay [22]. Thisﬁnding is in linewith
previous reports of normal angiogenesis in vWF−/−mice [105]. Platelet
GPIbα, however, may have a critical role, because replacement of its
extracellular domain did result in abnormal angiogenesis in the mouse
cornea model [22]. Beside vWF, this platelet receptor also binds to
endothelial P-selectin [106].
P-selectin, one of the three members of the selectin family of
adhesion molecules is of potential interest in platelet-dependent
angiogenesis. P-selectin is synthesized and stored in Weibel–Palade
bodies of endothelial cells and in α-granules of platelets [107]. Upon
stimulation, P-selectin is exocytosed to the outer surface of activated
endothelial cells and platelets, where it interactswith its ligands [107].
Like vWF, endothelial P-selectin can support rolling of platelets
through interactions with either GP1bα or PSGL-1 on platelets [106].
In a study focusing on ischemia, P-selectin mediated platelet adhesion
to the vessel wall appeared to be a key event to enhance local
angiogenesis [108]. P-selectin seems to be involved in cancer as well,
as P-selectin knockout mice showed a signiﬁcant reduction in tumor
growth and metastasis, while at the same time platelets failed to
adhere to tumor cell surface [109]. Furthermore, inhibition of P-
selectin by heparin treatment reducing platelet interactions with
tumor cells and possibly endothelial cells as well appeared to
attenuate metastasis in tumor bearing mice [110].
Fibrin(ogen) may also play an important role in platelet adhesion
during tumor growth and angiogenesis as tumors have leaky vessels
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deposited on the luminal endothelial cell surface. Furthermore, tumor
cells are able to express different factors on their surface that are
involved in the regulation of ﬁbrin(ogen) [83–86,111]. This provides
platelets with an ideal substrate to which they can adhere. Integrin
αIIbβ3 is the main platelet receptor for ﬁbrinogen and has an essential
role in platelet aggregation and activation in malignancies [112–114].
Inhibition of αIIbβ3 by a humanized monoclonal antibody c7E3 Fab
(abciximab; ReoPro) has been shown to reduce platelet stimulated
capillary formation in different angiogenesis assays [115]. In a model of
hypoxia-induced retinal angiogenesis inhibition of αIIbβ3 by another
speciﬁc antagonist reduced retinal neovascularization by 35% [105].
In case of endothelial denudation, components of the ECM may
play a role in platelet–vessel wall interactions. The most important
thrombogenic subendothelial ECM component is collagen, as it not
only supports platelet adhesion but also acts as an important platelet
activator [116–118]. A large number of collagen receptors have been
identiﬁed on platelets [118–120], but GPVI appears to be the most
potent and important one [36,121]. In tumors, collagen exposure to
bloodmay be the result of ECM and endothelial cell lining degradation
by matrix metalloproteinases during the angiogenic process [122].
Moreover, procollagen molecules collagen 1α1 and collagen IV-α are
overexpressed on activated endothelial cells in different tumor types
[123]. To our knowledge, it is not yet known whether GPVI, collagen
and/or the procollagen molecules are involved in tumor angiogenesis.
The above data suggest an upregulation of endothelial (adhesion)
molecules such as TF, vWF andmaybe also P-selectin in a proangiogenic
or malignant environment, which may contribute to local platelet
adhesion. At the same time, it is already known that tumor-derivedFig. 2. 1) Platelets contain a whole range of pro- and antiangiogenic compounds which ar
subsequently activated in tumor vasculature. 3) Platelets secrete their pro- and antiangiogen
not correct).angiogenic growth factors downregulate other endothelial adhesion
molecules that are involved in interactions between leukocytes and
endothelial cells [124,125]. Downregulation of adhesion molecules like
VCAM-1, ICAM-1 and E-selectin enables tumors to escape from immune
surveillance [95,124]. This endothelial cell anergy can be reversed by
administration of angiostatic factors such as anginex or endostatin,
resulting in normalization of leukocyte adhesion and inﬁltration in
tumors [8,126].
Clearly, tumor-derived endothelial cells are phenotypically and
functionally different from endothelial cells in healthy tissues [127].
These differences may provide attractive targets for speciﬁc cancer
therapy, but also offer possibilities for platelets to adhere to the vessel
wall with subsequent activation and secretion of growth factors.
Although platelets contain both pro- and antiangiogenic factors their
overall effect appears tobeproangiogenic [22,41,69,128]. Therefore, one
could hypothesize that selective blockade of platelet–endothelium
interactions in tumor vessels inhibits platelet activation and secretion
and, hence, platelet-dependent angiogenesis, which may lead to
reduced tumor growth. The fact that platelets have been shown to be
able to selectively releasepro- andantiangiogenic proteins suggests that
they can contribute to ﬁne-tuning of the angiogenesis process. Future
studies have to elucidate the signals that control the balance and timing
of the release of pro- and antiangiogenic factors within tumors.
5. Concluding remarks
Our current understanding regarding the role of platelets in tumor
angiogenesis is still modest, but a number of important facts illustrate
the potential signiﬁcance of platelets in malignancies (Fig. 2).e endocytosed and sequestered in different α-granules. 2) Platelets adhere to and are
ic content in tumor vasculature. (For reasons of clarity the scale of cells and granules is
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compounds, which are endocytosed and sequestered in different
populations of α-granules. (ii) Tumor vasculature and endothelial
cells are phenotypically and functionally different from endothelial
cells in healthy tissue, causing adhesion and subsequent activation of
platelets. (iii) Platelets secrete their angiogenic and angiostatic
content upon activation, possibly in a regulated way. The overall
effect of platelet activation on endothelial cells appears to be
proangiogenic, stimulating tumor angiogenesis.
Selective inhibition of platelet–endothelium interactions, using
speciﬁc phenotypic characteristics of tumor endothelial cells as target,
may therefore be a potentially interesting therapeutic tool to reduce
tumor angiogenesis and, hence, tumor growth. One could also use the
proposed link between the platelet PAR receptors and their secretion of
pro- or antiangiogenic agents tomodulate tumor angiogenesis. Selective
stimulationof theplatelet PAR-4 receptormay for example inhibit tumor
angiogenesis by suppression of VEGF secretion and simultaneous
enhancement of the release of endostatin; in this way, the body's own
angiostatic ability is utilized to inhibit tumor vascularisation andgrowth.
Reduction of drug-induced resistance has been suggested to be
one of the advantages of angiogenesis inhibitors. However, effects of
current angiogenesis inhibitors like bevacizumab (Avastin) and
sunitinib (Sutent) do not support this; they increase life expectancy
by only a few months as tumors do become resistant to these drugs
and produce other growth factors as a form of compensation [129].
Speciﬁc blockade of platelet–endothelial interactions in cancer
therapy may decrease drug-induced resistance as it does not
counteract one growth factor like VEGF as Avastin does. Moreover,
inhibition of platelet–endothelial interactions at the level of the
endothelial cells may offer additional advantages, as endothelial cells
are genetically more stable than tumor cells.
Combination of our knowledge about the role of platelets in
hemostasis with that of platelet behavior in tumor angiogenesis may
lead to useful hypotheses about new forms of cancer therapy. By
unravelling the underlying mechanisms of platelet–endothelial cell
interactions in tumors we will not only be able to reduce the
coagulation abnormalities in cancer patients, but we may also be able
to speciﬁcally target these interactions in the treatment of angiogen-
esis dependent diseases such as cancer.References
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